HSBC has initiated its coverage of SRF with a buy rating and the target price at Rs 3,390. Analysts said SRF was one of India’s largest chemical manufacturing companies, with 50% of its revenue coming from overseas. Improving fundamentals in specialty chemicals and performance films to drive a 26% compounded annual growth rate (CAGR) of earnings during FY27-FY29.They see some risks in the refrigerant gas segment. Analysts also pointed out some key downside risks that include tariffs/anti-dumping duties, further price declines, West Asia crisis leading to raw material shortages, and higher inventories in the agro-chemicals segment.Jefferies has a buy rating on Grasim with the target price at Rs 3,440. Analysts said Grasim is set to receive Rs 397 crore from UltraTech Cement’s Rs 240/share payout in Q4FY26, a sharp step-up compared to the prior years. Past two years suggested Grasim has retained half of the dividend to fund new businesses, particularly paints.With dividend pool from UltraTech structurally looking higher, Grasim now has greater capital availability with optionality across growth funding, deleveraging, and shareholder returns – and, if executed prudently, scope to narrow the holdco discount.Nomura has a buy on Adani Ports & SEZ with the target price at Rs 1,930. Analysts said the company’s sub-sea foray in Europe to bolster marine business. And its Europe expansion significantly increases the marine segment’s international footprint. They feel that the company’s operational capabilities will be enhanced by the addition of Astro Atlas vessel. By FY31, in the marine segment, ADSEZ aims to have about 200 vessels, revenue of Rs 6,000 crore, and capex of R 13,000 crore, which appear largely achievable.CLSA has a hold rating on Tata Power with the target price at Rs 415, up from the earlier target at Rs 369. Analysts said FY26 was a weak year. During Q4FY26, Mundra IPP and solar EPC disappointed while coal mines shone. During FY26, Mundra IPP loss and slower solar EPC and RE IPP hurt but they feel the worst is behind already.Goldman Sachs has a buy on Neuland Labs with the target price at Rs 19,550, up from the earlier target at Rs 17,275. Analysts said the Q4FY26 numbers were above estimates with generic drug substance inline as contract development & manufacturing (CDMO) drove the stellar beat. EBITDA margin came in at 40% on the back of a better product mix as well as operating leverage.Analysts expect topline growth to remain robust at 20%+ CAGR over FY26-FY28. They hiked FY27-FY29 earnings per share (EPS) estimates by up to 8% to factor in the Q4 beat, updated pipeline progress and revised business outlook as discussed by the management.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)
